These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
923 related articles for article (PubMed ID: 8623494)
1. Conversion from cyclosporine to tacrolimus in kidney, kidney/pancreas, and pancreas alone transplant recipients: the Memphis experience. Alloway RR; Russell WC; Gaber LW; Amiri MH; Vera SR; Gaber AO Transplant Proc; 1996 Apr; 28(2):995-7. PubMed ID: 8623494 [No Abstract] [Full Text] [Related]
2. Role of protocol biopsies in the treatment of refractory renal allograft rejection with FK 506. Woodle ES; Thistlethwaite JR; Haas M; Josephson MA; Newell KA; Bruce DS; Millis JM; Piper JB; Charette JI Transplant Proc; 1996 Apr; 28(2):998-9. PubMed ID: 8623495 [No Abstract] [Full Text] [Related]
3. FK 506 induction and rescue therapy in pancreas transplant recipients. Stratta RJ; Taylor RJ; Castaldo P; Sindhi R; Sudan D; Weide LG; Frisbie K; Cushing KA; Jerius J; Radio SJ Transplant Proc; 1996 Apr; 28(2):991-2. PubMed ID: 8623492 [No Abstract] [Full Text] [Related]
4. Comparison between three different antilymphocyte induction protocols in renal transplant recipients with delayed graft function. Sumrani N; Hong JH; DiBenedetto A; Clayton R; Miles AM; Markell MS; Distant DA; Fleishhacker J; Sommer BG Transplant Proc; 1996 Feb; 28(1):400-1. PubMed ID: 8644289 [No Abstract] [Full Text] [Related]
5. Efficacy and safety of tacrolimus versus cyclosporine in kidney and pancreas transplant recipients. el-Ghoroury M; Hariharan S; Peddi VR; Munda R; Schroeder TJ; Demmy AM; Alexander JW; First MR Transplant Proc; 1997; 29(1-2):649-51. PubMed ID: 9123461 [No Abstract] [Full Text] [Related]
6. Correlation of clinical outcomes after tacrolimus conversion for resistant kidney rejection or cyclosporine toxicity with pathologic staging by the Banff criteria. Morrissey PE; Gohh R; Shaffer D; Crosson A; Madras PN; Sahyoun AI; Monaco AP Transplantation; 1997 Mar; 63(6):845-8. PubMed ID: 9089224 [TBL] [Abstract][Full Text] [Related]
7. FK 506 in the treatment of steroid- and OKT3-resistant rejection in renal transplant recipients: reduced dosage and anti-infective prophylaxis. Kliem V; Eberhard OK; Oldhafer K; Schlitt HJ; Behrend M; Schaumann D; Pichlmayr R; Koch KM; Brunkhorst R Transplant Proc; 1996 Dec; 28(6):3166-8. PubMed ID: 8962227 [No Abstract] [Full Text] [Related]
8. Neoquadruple induction with antithymocyte globulin/azathioprine/cyclosporine/prednisolone in simultaneous pancreas and kidney transplant recipients: 8.5-year results. Schulz T; Kapischke M; Busing M Transplant Proc; 2005 May; 37(4):1815-7. PubMed ID: 15919475 [TBL] [Abstract][Full Text] [Related]
9. OKT3 first-line treatment of acute rejection episodes following combined pancreas and kidney transplantation. Cantarovich D; Hourmant M; Dantal J; Giral M; Paineau J; Karam G; Soulillou JP Transplant Proc; 1994 Apr; 26(2):549. PubMed ID: 8171548 [No Abstract] [Full Text] [Related]
11. Cyclosporine therapy in pancreas transplantation. Davidson I; Lu C; Melone D; Risser R Transplant Proc; 1996 Aug; 28(4):2134-5. PubMed ID: 8769179 [No Abstract] [Full Text] [Related]
12. Mycophenolate mofetil versus azathioprine in simultaneous pancreas-kidney transplant recipients on cyclosporine. Fabrega AJ; Corwin CL; Hunsicker L Transplant Proc; 1998 Jun; 30(4):1562-3. PubMed ID: 9636634 [No Abstract] [Full Text] [Related]
13. A double-blind randomized study of Sandimmun Neoral versus Sandimmun in new renal transplant recipients: results after 12 months. The International Sandimmun Neoral Study Group. Niese D Transplant Proc; 1995 Apr; 27(2):1849-56. PubMed ID: 7725531 [No Abstract] [Full Text] [Related]
14. Outcome of monoclonal antibody induction and anti-rejection therapy in pancreas transplantation. Bruce DS; Newell KA; Woodle ES; Millis JM; Piper JB; Huss E; Thistlethwaite JR Transplant Proc; 1996 Aug; 28(4):2136-7. PubMed ID: 8769180 [No Abstract] [Full Text] [Related]
15. Comparison of OKT3 and antithymocyte globulin as induction immunosuppressive agents in renal transplantation. Kitabayashi K; Munn SR; Sterioff S Transplant Proc; 1996 Jun; 28(3):1973-5. PubMed ID: 8658964 [No Abstract] [Full Text] [Related]
16. Influence of immunosuppressive therapy on infectious complications in renal transplant recipients. Klauser R; Zlabinger GJ; Traindl O; Franz M; Watschinger B; Pohanka E; Kudlacek S; Kovarik J Transplant Proc; 1992 Feb; 24(1):292-4. PubMed ID: 1539284 [No Abstract] [Full Text] [Related]
17. Tacrolimus (FK 506) therapy in simultaneous pancreas kidney transplantation. Becker G; Witzke O; Friedrich J; Wagner K; Heemann U; Philipp T Transplant Proc; 1996 Dec; 28(6):3169-70. PubMed ID: 8962228 [No Abstract] [Full Text] [Related]
18. High-dose cyclosporine A induction therapy in liver transplant recipients with normal postoperative renal function: a prospective study. Cherqui D; Duvoux C; Salvat A; Lauzet JY; Metreau JM; Julien M; Fagniez PL; Dhumeaux D Transplant Proc; 1995 Feb; 27(1):1134-5. PubMed ID: 7878824 [No Abstract] [Full Text] [Related]
19. Conversion from cyclosporine to tacrolimus in hepatic and renal transplantation. Yussim A; Shaharabani E; Mor E; Lustig S; Bar-Nathan N; Shmueli D; Sobolev V; Dorfman B; Or H; Shapira Z Transplant Proc; 1996 Dec; 28(6):3178-9. PubMed ID: 8962233 [No Abstract] [Full Text] [Related]